{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptans&page=53", "query": { "intervention": "Triptans", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 1256, "total_pages": 126, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptans&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptans&page=52&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T08:46:35.392Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00146549", "title": "Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2001-08", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2009-11-02", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00146549" }, { "nct_id": "NCT02574455", "title": "Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sacituzumab govitecan", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 529, "start_date": "2017-11-07", "completion_date": "2020-12-08", "has_results": true, "last_update_posted_date": "2022-06-15", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 185, "location_summary": "Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 144 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574455" }, { "nct_id": "NCT00688935", "title": "Young Blind Child Melatonin Treatment Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Blindness" ], "interventions": [ { "name": "Melatonin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Year to 20 Years" }, "enrollment_count": 9, "start_date": "2005-01", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00688935" }, { "nct_id": "NCT01222715", "title": "Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Rhabdomyosarcoma", "Childhood Alveolar Rhabdomyosarcoma", "Childhood Pleomorphic Rhabdomyosarcoma", "Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Childhood Rhabdomyosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Vinorelbine Tartrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "29 Years", "sex": "ALL", "summary": "Up to 29 Years" }, "enrollment_count": 87, "start_date": "2010-10", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-05-05", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 163, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222715" }, { "nct_id": "NCT00877006", "title": "Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "bendamustine", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 447, "start_date": "2009-04-30", "completion_date": "2012-03-31", "has_results": true, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 79, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877006" }, { "nct_id": "NCT03368352", "title": "Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Altitude Hypoxia", "Ventilation", "Sleep", "Oxidative Stress", "Neurocognitive Dysfunction" ], "interventions": [ { "name": "Melatonin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Hypoxia", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2017-07-04", "completion_date": "2018-12-20", "has_results": false, "last_update_posted_date": "2019-01-31", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03368352" }, { "nct_id": "NCT07909408", "title": "Psilocybin FCR Early-Stage Breast Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early-stage Breast Cancer", "Fear of Cancer Recurrence", "Anxiety", "Depression" ], "interventions": [ { "name": "Psilocybin 25 mg", "type": "DRUG" }, { "name": "Psilocybin 5 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2027-01-02", "completion_date": "2031-08-31", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 2, "location_summary": "Aurora, Colorado • New York, New York", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07909408" }, { "nct_id": "NCT00217425", "title": "Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2006-09-14", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 110, "location_summary": "Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217425" }, { "nct_id": "NCT00006215", "title": "Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 19, "location_summary": "Modesto, California • Washington D.C., District of Columbia • Riverdale, Georgia + 15 more", "locations": [ { "city": "Modesto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Riverdale", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006215" }, { "nct_id": "NCT00002715", "title": "Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "Stanford V regimen", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Mechlorethamine hydrochloride", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 50, "start_date": "1989-04", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-11-09T08:46:35.392Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002715" } ] }